Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;51(1):295-303.
doi: 10.1007/s00259-023-06380-4. Epub 2023 Aug 18.

Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management

Shivanshan Pathmanathan  1 , Arsalan Tariq  2   3 , Adam Pearce  2   3   4 , Handoo Rhee  3   5 , Samuel Kyle  6   7 , Sheliyan Raveenthiran  2   8 , David Wong  9 , Rhiannon McBean  9 , Phillip Marsh  10 , Steven Goodman  7 , Nattakorn Dhiantravan  7 , Rachel Esler  2   4 , Nigel Dunglison  2   3 , Anojan Navaratnam  2   3 , John Yaxley  2   3   4 , Paul Thomas  3   7 , David A Pattison  3   7 , Jeffrey C Goh  1   3 , Chun Loo Gan  1 , Matthew J Roberts  11   12   13   14
Affiliations

Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management

Shivanshan Pathmanathan et al. Eur J Nucl Med Mol Imaging. 2023 Dec.

Abstract

Purpose: There is an emerging role of the use of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in renal cell carcinoma. Herein, we report our experience in use of PSMA PET in recurrent or metastatic renal cell carcinoma (RCC).

Methods: A retrospective analysis of all patients who underwent PSMA PET for suspected recurrent or de-novo metastatic RCC between 2015 and 2020 at three institutions was performed. The primary outcome was change in management (intensification or de-intensification) following PSMA PET scan. Secondary outcomes included histopathological correlation of PSMA avid sites, comparison of sites of disease on PSMA PET to diagnostic CT and time to systemic treatment.

Keywords: Management; Positron emission tomography; Prostate specific membrane antigen; Renal cell carcinoma; Staging.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non-financial interests to disclose.

Figures

Fig. 1
Fig. 1
Study profile
Fig. 2
Fig. 2
Sankey diagrams representing treatment before and after PSMA PET in the recurrent disease group (A) and metastatic disease group (B)
Fig. 3
Fig. 3
Comparison of PSMA PET compared to CT. A shows better delineation of metastatic disease than CT, B refuted suspected metastatic disease on CT
See this image and copyright information in PMC

References

    1. Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, et al. Epidemiology of Renal Cell Carcinoma. World J Oncol. 2020;11:79–87. doi: 10.14740/wjon1279. - DOI - PMC - PubMed
    1. Ahn T, Roberts MJ, Abduljabar A, Joshi A, Perera M, Rhee H, et al. A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC) Mol Imaging Biol. 2019;21:799–807. doi: 10.1007/s11307-018-01307-0. - DOI - PubMed
    1. Tyson MD, Chang SS. Optimal Surveillance Strategies After Surgery for Renal Cell Carcinoma. J Natl Compr Canc Netw. 2017;15:835–840. doi: 10.6004/jnccn.2017.0102. - DOI - PubMed
    1. Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998;16:2261–2266. doi: 10.1200/JCO.1998.16.6.2261. - DOI - PubMed
    1. Tang C, Msaouel P, Hara K, Choi H, Le V, Shah AY, et al. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. 2021;22:1732–1739. doi: 10.1016/S1470-2045(21)00528-3. - DOI - PMC - PubMed

MeSH terms

Substances